Impact of presentation timing in metastatic hormone‐sensitive prostate cancer: Characterization of patients and identification of prognostic factors

Documenti analoghi

• Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
  di: Takafumi Yanagisawa, et al.
  Pubblicazione: (2024)
• Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real‐world setting of metastatic hormone‐sensitive prostate cancer patients
  di: Mike Wenzel, et al.
  Pubblicazione: (2024)
• Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
  di: Shintaro Narita, et al.
  Pubblicazione: (2024)
• Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone‐sensitive prostate cancer
  di: Mike Wenzel, et al.
  Pubblicazione: (2024)
• Deep PSA response and extended time‐to‐nadir as robust predictors of survival in Asian patients with de novo metastatic hormone‐sensitive prostate cancer receiving upfront intensified treatment
  di: Chris H.‐M. Wong, et al.
  Pubblicazione: (2024)